Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $EWTX vs $LGND | Chartloom

Compare

$EWTX vs $LGND

Edgewise Therapeutics Inc · Ligand Pharmaceuticals Inc

EWTX

Edgewise Therapeutics Inc

LGND

Ligand Pharmaceuticals Inc

Compare $EWTX vs $LGND

Comparing Edgewise Therapeutics Inc and Ligand Pharmaceuticals Inc

EWTXEdgewise Therapeutics Inc

LGNDLigand Pharmaceuticals Inc

EWTXEdgewise Therapeutics Inc

Market cap

$3.90B

P/E (TTM)

—

Forward P/E (NTM)

19.86x

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

52.8%

52W performance

140.1%

FCF yield

-4.1%

LGNDLigand Pharmaceuticals Inc

Market cap

$6.08B

P/E (TTM)

33.61x

Forward P/E (NTM)

28.81x

Forward P/S (NTM)

17.73x

Rev growth (TTM)

54.9%

YTD performance

59.7%

52W performance

70.8%

FCF yield

2.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EWTX

LGND

Detailed metrics comparison

EWTX

Edgewise Therapeutics Inc

LGND

Ligand Pharmaceuticals Inc

Market Cap

EWTX$3.90B

LGND$6.08B

Enterprise Value

EWTX$3.83B

LGND$6.20B

Price

EWTX$36.28

LGND$303.53

P/E Ratio

EWTXN/A

LGND33.61x

P/S Ratio

EWTX0.00x

LGND20.94x

EV/Sales

EWTX0.00x

LGND21.35x

EV/EBITDA

EWTX0.00x

LGND42.81x

P/B Ratio

EWTX9.47x

LGND6.22x

P/FCF Ratio

EWTXN/A

LGND45.31x

EV/FCF

EWTX-24.12x

LGND46.20x

PEG Ratio

EWTXN/A

LGND1.33x

Forward P/E (NTM)

EWTX19.86x

LGND28.81x

Forward P/S (NTM)

EWTXN/A

LGND17.73x

Revenue (TTM)

EWTX$0

LGND$291M

Revenue Growth (YoY)

EWTXN/A

LGND54.9%

Forward Rev Growth

EWTX0.0%

LGND31.3%

Gross Margin (TTM)

EWTX0.0%

LGND95.4%

Operating Margin (TTM)

EWTX0.0%

LGND32.6%

EBITDA Margin (TTM)

EWTX0.0%

LGND45.8%

Net Margin (TTM)

EWTX0.0%

LGND67.9%

FCF Margin (TTM)

EWTXN/A

LGND46.2%

Net Income (TTM)

EWTX$-197M

LGND$197M

FCF (TTM)

EWTX$-159M

LGND$134M

EPS (TTM)

EWTX-$1.83

LGND$9.03

ROE (TTM)

EWTX-3901.0%

LGND20.1%

ROA (TTM)

EWTX-3696.0%

LGND11.7%

ROIC (TTM)

EWTX-3901.0%

LGND12.3%

Cash

EWTX$72M

LGND$1.01B

Debt

EWTX$0

LGND$1.13B

Net Cash/Debt

EWTX$72M

LGND$-120M

Current Ratio (TTM)

EWTX16.24x

LGND31.18x

Quick Ratio (TTM)

EWTX16.01x

LGND30.96x

Debt/Equity (TTM)

EWTX0.00x

LGND1.16x

Debt/Assets (TTM)

EWTX0.0%

LGND0.0%

Interest Coverage (TTM)

EWTXN/A

LGNDN/A

Net Debt/EBITDA (TTM)

EWTX0.00x

LGND0.00x

Beta

EWTX0.37

LGND1.23

52W Performance

EWTX140.1%

LGND70.8%

YTD Performance

EWTX52.8%

LGND59.7%

% from 52W High

EWTX-25.2%

LGND-7.1%

% from 52W Low

EWTX154.6%

LGND72.6%

Asset Turnover (TTM)

EWTX0.00x

LGND0.17x

FCF Yield (TTM)

EWTX-4.1%

LGND2.2%

Earnings Yield (TTM)

EWTX-5.1%

LGND3.2%

Dividend Yield (TTM)

EWTXN/A

LGNDN/A

Rule of 40

EWTX0.0

LGND101.1

EV/GP/RG

EWTXN/A

LGND1.14

Ticker research

View EWTX research View LGND research

Metric	EWTX Edgewise Therapeutics Inc	LGND Ligand Pharmaceuticals Inc
Market & Valuation
Market Cap	$3.90B	$6.08B
Enterprise Value	$3.83B	$6.20B
Price	$36.28	$303.53
P/E Ratio	N/A	33.61x
P/S Ratio	0.00x	20.94x
EV/Sales	0.00x	21.35x
EV/EBITDA	0.00x	42.81x
P/B Ratio	9.47x	6.22x
P/FCF Ratio	N/A	45.31x
EV/FCF	-24.12x	46.20x
PEG Ratio	N/A	1.33x
Forward P/E (NTM)	19.86x	28.81x
Forward P/S (NTM)	N/A	17.73x
Revenue & Growth
Revenue (TTM)	$0	$291M
Revenue Growth (YoY)	N/A	54.9%
Forward Rev Growth	0.0%	31.3%
Profitability
Gross Margin (TTM)	0.0%	95.4%
Operating Margin (TTM)	0.0%	32.6%
EBITDA Margin (TTM)	0.0%	45.8%
Net Margin (TTM)	0.0%	67.9%
FCF Margin (TTM)	N/A	46.2%
Net Income (TTM)	$-197M	$197M
FCF (TTM)	$-159M	$134M
EPS (TTM)	-$1.83	$9.03
ROE (TTM)	-3901.0%	20.1%
ROA (TTM)	-3696.0%	11.7%
ROIC (TTM)	-3901.0%	12.3%
Financial Health
Cash	$72M	$1.01B
Debt	$0	$1.13B
Net Cash/Debt	$72M	$-120M
Current Ratio (TTM)	16.24x	31.18x
Quick Ratio (TTM)	16.01x	30.96x
Debt/Equity (TTM)	0.00x	1.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.37	1.23
52W Performance	140.1%	70.8%
YTD Performance	52.8%	59.7%
% from 52W High	-25.2%	-7.1%
% from 52W Low	154.6%	72.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.17x
FCF Yield (TTM)	-4.1%	2.2%
Earnings Yield (TTM)	-5.1%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	101.1
EV/GP/RG	N/A	1.14
Ticker research	View EWTX research	View LGND research

Valuation

P/E Ratio

LGND

33.61x

P/S Ratio

EWTX

0.00x

LGND

20.94x

EV/FCF

EWTX

-24.12x

LGND

46.20x

Growth & revenue

Revenue Growth TTM

LGND

54.9%

Forward Revenue Growth

LGND

31.3%

EWTX

0.0%

Profitability & performance

Gross Margin

LGND

95.4%

EWTX

0.0%

ROE

LGND

20.1%

EWTX

-3901.0%

FCF Yield %

LGND

2.2%

EWTX

-4.1%

52-Week Performance

EWTX

140.1%

LGND

70.8%

Detailed metrics comparison

EWTX

Edgewise Therapeutics Inc

LGND

Ligand Pharmaceuticals Inc

Market Cap

EWTX$3.90B

LGND$6.08B

Enterprise Value

EWTX$3.83B

LGND$6.20B

Price

EWTX$36.28

LGND$303.53

P/E Ratio

EWTXN/A

LGND33.61x

P/S Ratio

EWTX0.00x

LGND20.94x

EV/Sales

EWTX0.00x

LGND21.35x

EV/EBITDA

EWTX0.00x

LGND42.81x

P/B Ratio

EWTX9.47x

LGND6.22x

P/FCF Ratio

EWTXN/A

LGND45.31x

EV/FCF

EWTX-24.12x

LGND46.20x

PEG Ratio

EWTXN/A

LGND1.33x

Forward P/E (NTM)

EWTX19.86x

LGND28.81x

Forward P/S (NTM)

EWTXN/A

LGND17.73x

Revenue (TTM)

EWTX$0

LGND$291M

Revenue Growth (YoY)

EWTXN/A

LGND54.9%

Forward Rev Growth

EWTX0.0%

LGND31.3%

Gross Margin (TTM)

EWTX0.0%

LGND95.4%

Operating Margin (TTM)

EWTX0.0%

LGND32.6%

EBITDA Margin (TTM)

EWTX0.0%

LGND45.8%

Net Margin (TTM)

EWTX0.0%

LGND67.9%

FCF Margin (TTM)

EWTXN/A

LGND46.2%

Net Income (TTM)

EWTX$-197M

LGND$197M

FCF (TTM)

EWTX$-159M

LGND$134M

EPS (TTM)

EWTX-$1.83

LGND$9.03

ROE (TTM)

EWTX-3901.0%

LGND20.1%

ROA (TTM)

EWTX-3696.0%

LGND11.7%

ROIC (TTM)

EWTX-3901.0%

LGND12.3%

Cash

EWTX$72M

LGND$1.01B

Debt

EWTX$0

LGND$1.13B

Net Cash/Debt

EWTX$72M

LGND$-120M

Current Ratio (TTM)

EWTX16.24x

LGND31.18x

Quick Ratio (TTM)

EWTX16.01x

LGND30.96x

Debt/Equity (TTM)

EWTX0.00x

LGND1.16x

Debt/Assets (TTM)

EWTX0.0%

LGND0.0%

Interest Coverage (TTM)

EWTXN/A

LGNDN/A

Net Debt/EBITDA (TTM)

EWTX0.00x

LGND0.00x

Beta

EWTX0.37

LGND1.23

52W Performance

EWTX140.1%

LGND70.8%

YTD Performance

EWTX52.8%

LGND59.7%

% from 52W High

EWTX-25.2%

LGND-7.1%

% from 52W Low

EWTX154.6%

LGND72.6%

Asset Turnover (TTM)

EWTX0.00x

LGND0.17x

FCF Yield (TTM)

EWTX-4.1%

LGND2.2%

Earnings Yield (TTM)

EWTX-5.1%

LGND3.2%

Dividend Yield (TTM)

EWTXN/A

LGNDN/A

Rule of 40

EWTX0.0

LGND101.1

EV/GP/RG

EWTXN/A

LGND1.14

Ticker research

View EWTX research View LGND research

Metric	EWTX Edgewise Therapeutics Inc	LGND Ligand Pharmaceuticals Inc
Market & Valuation
Market Cap	$3.90B	$6.08B
Enterprise Value	$3.83B	$6.20B
Price	$36.28	$303.53
P/E Ratio	N/A	33.61x
P/S Ratio	0.00x	20.94x
EV/Sales	0.00x	21.35x
EV/EBITDA	0.00x	42.81x
P/B Ratio	9.47x	6.22x
P/FCF Ratio	N/A	45.31x
EV/FCF	-24.12x	46.20x
PEG Ratio	N/A	1.33x
Forward P/E (NTM)	19.86x	28.81x
Forward P/S (NTM)	N/A	17.73x
Revenue & Growth
Revenue (TTM)	$0	$291M
Revenue Growth (YoY)	N/A	54.9%
Forward Rev Growth	0.0%	31.3%
Profitability
Gross Margin (TTM)	0.0%	95.4%
Operating Margin (TTM)	0.0%	32.6%
EBITDA Margin (TTM)	0.0%	45.8%
Net Margin (TTM)	0.0%	67.9%
FCF Margin (TTM)	N/A	46.2%
Net Income (TTM)	$-197M	$197M
FCF (TTM)	$-159M	$134M
EPS (TTM)	-$1.83	$9.03
ROE (TTM)	-3901.0%	20.1%
ROA (TTM)	-3696.0%	11.7%
ROIC (TTM)	-3901.0%	12.3%
Financial Health
Cash	$72M	$1.01B
Debt	$0	$1.13B
Net Cash/Debt	$72M	$-120M
Current Ratio (TTM)	16.24x	31.18x
Quick Ratio (TTM)	16.01x	30.96x
Debt/Equity (TTM)	0.00x	1.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.37	1.23
52W Performance	140.1%	70.8%
YTD Performance	52.8%	59.7%
% from 52W High	-25.2%	-7.1%
% from 52W Low	154.6%	72.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.17x
FCF Yield (TTM)	-4.1%	2.2%
Earnings Yield (TTM)	-5.1%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	101.1
EV/GP/RG	N/A	1.14
Ticker research	View EWTX research	View LGND research